Cited by 241Alzheimer's disease research and treatmentsGut microbiota and healthNeuroinflammation and Neurodegeneration Mechanisms

Mannan oligosaccharide attenuates cognitive and behavioral disorders in the 5xFAD Alzheimer's disease mouse model via regulating the gut microbiota-brain axis

Liu, Qing, Xi, Yujia, Wang, Qianxu, Liu, Jinhui, Li, Peiran, Meng, Xue, Liu, Kai, Chen, Weixuan +2 more·2021·Brain, Behavior, and Immunity

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive deficits and psychiatric symptoms. The gut microbiota-brain axis plays a pivotal role during AD development, which could target nutritional intervention. The prebiotic mannan oligosaccharide (MOS) has been reported to reshape the gut microbiome and enhanced the formation of the neuroprotective metabolites short-chain fatty acids (SCFAs). Here, we found that an 8-week treatment of MOS (0.12%, w/v in the drinking water) significantly improved cognitive function and spatial memory, accompanied by attenuated the anxiety- and obsessive-like behaviors in the 5xFAD transgenic AD mice model. MOS substantially reduced the Aβ accumulation in the cortex, hippocampus, and amygdala of the brain. Importantly, MOS treatment significantly balanced the brain redox status and suppressed the neuroinflammatory responses. Moreover, MOS also alleviated the HPA-axis disorders by decreasing the levels of hormones corticosterone (CORT) and corticotropin-releasing hormone (CRH) and upregulated the norepinephrine (NE) expressions. Notably, the gut barrier integrity damage and the LPS leak were prevented by the MOS treatment. MOS re-constructed the gut microbiota composition, including increasing the relative abundance of Lactobacillus and reducing the relative abundance of Helicobacter. MOS enhanced the butyrate formation and related microbes levels. The correlation analysis indicated that the reshaped gut microbiome and enhanced butyrate formation are highly associated with behavioral alteration and brain oxidative status. SCFAs supplementation experiment also attenuated the behavioral disorders and Aβ accumulation in the AD mice brain, accompanied by balanced HPA-axis and redox status. In conclusion, the present study indicated that MOS significantly attenuates the cognitive and mental deficits in the 5xFAD mice, which could be partly explained by the reshaped microbiome and enhanced SCFAs formation in the gut. MOS, as a prebiotics, can be translated into a novel microbiota-targeted approach for managing metabolic and neurodegenerative diseases.

Integrity signals

Registry

Crossref · 10.1016/j.bbi.2021.04.005

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Probiotic and prebiotic interventions aimed at elevating SCFA levels have neuroprotective effects in AD mouse models by inhibiting glial activation and Aβ deposition.

    “Moreover, probiotic and prebiotic interventions aimed at elevating SCFA levels have demonstrated neuroprotective effects in AD mouse models by inhibiting glial activation and Aβ deposition.301–306”

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liu, Q., Xi, Y., Wang, Q., Liu, J., Li, P., Meng, X., Liu, K., Chen, W., Liu, X., & Liu, Z.
Affiliations
  • Northwest A&F University (CN)
  • Cornell University (US)
Corresponding author
  • Liu, Qing
  • Liu, Jinhui
  • Liu, Kai
  • Liu, Xuebo
  • Liu, Zhigang
Venue
Brain, Behavior, and Immunity
Publisher
Elsevier BV
Published
2021-07
Volume
95
Pages
330-343
ISSN
0889-1591 (ISSN-L)
OpenAlex
W3156209056
Cited by
241
References
84
Citations by year
2026: 40 · 2025: 66 · 2024: 60 · 2023: 43 · 2022: 26 · 2021: 6
FWCI
21.18
Type
journal article
Language
en
Open access
closed
Locations
  • Brain Behavior and Immunity (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alexander von Humboldt-Stiftung
  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
mannan oligosaccharides, Alzheimer's disease, 5xFAD mice, gut-brain axis, prebiotics, short-chain fatty acids, butyrate, amyloid-beta deposition, neuroinflammation, oxidative stress, hypothalamic-pituitary-adrenal axis, anxiety-like behavior, intestinal barrier integrity, LPS, Lactobacillus, Helicobacter, cognitive impairment, spatial memory
MeSH terms
Gastrointestinal Microbiome, Alzheimer Disease, Animals, Brain, Cognition, Mannans, Mice, Transgenic, Oligosaccharides, Neurodegenerative Diseases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review